• AO/PI Double Staining Kit: Practical Workflow

  2026-08-17

  The AO/PI Double Staining Kit provides a rapid fluorescent cell viability assay that separates viable, apoptotic-like, and membrane-compromised cell populations using Acridine Orange and Propidium Iodide. It is suitable for endpoint screening and microscopy-based cell death assessment, but it should not be treated as a standalone proof of a specific apoptotic pathway or as a substitute for orthogonal validation.

• Hyperthermia–Cisplatin Therapy Activates Caspase-8

  2026-08-17

  The reference study identifies caspase-8 accumulation and activation as a mechanistic link between hyperthermia–cisplatin treatment, apoptosis, and pyroptosis. Its experiments connect Cullin 3-dependent K63-linked polyubiquitination, p62 association, caspase-3 activation, and gasdermin processing, providing a framework for interpreting combination-treatment responses.

• Calpain Inhibitor I, ALLN: Practical Protocol Guide

  2026-08-16

  This guide explains how Calpain Inhibitor I, ALLN can be used to investigate calpain- and cathepsin-linked proteolysis in apoptosis, inflammation, and ischemia-reperfusion workflows. It is intended for controlled scientific experiments, not clinical, diagnostic, or therapeutic use, and its multi-protease activity means it should not be interpreted as a calpain-only intervention.

• Cisapride (R 51619): From Mechanism to Translation

  2026-08-15

  Cisapride is more than a serotonergic tool compound: its simultaneous activity at 5-HT4 receptors and hERG potassium channels creates a powerful bridge between mechanism-first biology and predictive cardiac safety. This thought-leadership guide shows how translational researchers can use Cisapride to connect receptor pharmacology, human iPSC-derived cardiomyocytes, deep-learning phenotyping, and decision-ready cardiac electrophysiology research.

• ATRA Restores Niraparib Sensitivity in Ovarian Cancer

  2026-08-14

  Mei and colleagues show that all-trans retinoic acid can reduce cisplatin-induced resistance to niraparib in epithelial ovarian cancer models. The study links this effect to suppression of an ALDH1A1–NAMPT–PARP1–CHK1 resistance program and reduced intracellular NAD+, supporting a maintenance-treatment strategy that targets acquired PARP inhibitor resistance.

• CRISPRi Targeting of Fabp4 Improves Obesity in Mice

  2026-08-14

  Chung and colleagues developed a nonviral, adipose-targeted CRISPR interference system that represses Fabp4 specifically in white adipocytes. In obese mice, this strategy reduced adiposity-associated inflammation and hepatic steatosis while improving insulin resistance, illustrating how tissue-selective gene regulation can address systemic metabolic disease.

• Carbapenemase Gene Spread in CREC, Guangdong

  2026-08-13

  A 2025 BMC Microbiology study combined gene localization, conjugation, mobile-element profiling, antimicrobial susceptibility testing, and ERIC-PCR to characterize carbapenem-resistant Enterobacter cloacae across eight teaching hospitals in Guangdong. Its central finding is that blaNDM-1 was common and highly transferable, highlighting the need to monitor both clonal spread and plasmid-mediated dissemination in antibiotic resistance research.

• Tofacitinib citrate: Applied Research Workflows

  2026-08-13

  Tofacitinib citrate supports controlled studies of JAK-STAT signaling, lymphocyte biology, and cytokine-driven inflammation. This guide translates its reported activity into practical immune-cell and endothelial workflows while emphasizing dose selection, vehicle control, and vascular safety readouts.

• Psoralen-Induced Cholestasis via ERK1/2 in Zebrafish

  2026-08-12

  Chen and colleagues show that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, induce cholestatic liver injury in zebrafish larvae through altered estrogen signaling and ERK1/2 phosphorylation. The study connects phytoestrogen exposure with bile acid synthesis and transport defects, while pharmacological rescue supports ERK1/2 as a mechanistically relevant target for further cholestasis research.

• Rosemary Root Lignans and Anti-Inflammatory Activity

  2026-08-12

  A January 2026 Fitoterapia study characterized eight lignans and four phenylpropanoids from Rosmarinus officinalis roots, including three previously unreported rosmarinicols. In an LPS-stimulated RAW264.7 macrophage assay, six compounds reduced nitric oxide production, identifying rosemary roots as a source of chemically diverse anti-inflammatory candidates for follow-up research.

• Exo1 Workflows for Exocytosis and TEV Research

  2026-08-11

  Exo1 enables acute membrane trafficking inhibition through a mechanism that distinguishes ARF1 release from Golgi membranes from BFA-associated effects. This guide translates that profile into practical exocytosis assays, extracellular vesicle workflows, controls, and troubleshooting strategies for preclinical cell research.

• AO/PI Double Staining Kit for Cell-Death Trajectories

  2026-08-11

  The AO/PI Double Staining Kit transforms rapid cell viability assay results into a time-resolved view of apoptosis and necrosis. This guide explains how to interpret fluorescence phenotypes alongside orthogonal evidence from a melanoma treatment study.

• 740 Y-P: PI 3-Kinase Activator Guide

  2026-08-10

  740 Y-P is a cell-permeable PI 3-kinase activator for controlled modulation of PI3K/AKT signaling in cell and biochemical research. Evidence spans vesicular trafficking, neuronal cell survival, melanoma-cell models, and pathway validation in mitophagy research.

• Deferasirox Fe3+ Chelate in Lysosome Research

  2026-08-09

  Use Deferasirox Fe3+ chelate as a controlled chemical probe when studying ferric-iron handling, glucose starvation, ferritinophagy, and lysosome-dependent cell death. This workflow combines solvent-aware formulation with the TCF25–V-ATPase findings from a recent CRISPR study to improve mechanistic resolution without confusing a preformed Fe3+ complex with free deferasirox.

• DiI (DiIC18(3)) Plasma Membrane Probe

  2026-08-08

  DiI (DiIC18(3)) provides orange-red labeling of lipid membranes for live or fixed-cell imaging, neuronal tracing, migration studies, and membrane-associated assays. It is lipophilic and water-insoluble, so it should not be selected for aqueous-only workflows or experiments requiring exclusive intracellular organelle staining.

764 records 7/51 page Previous Next First page 上5页 678910 下5页 Last page